ETNB רווח נקי למניה ב-12 החודשים האחרונים 89bio.com
Earnings per share over the last 12 months for 89bio, Inc. (ETNB) reflect a trend where the metric reached -3.58. The current trend is driven by a lack of operating leverage due to the testing phase. R&D efficiency is increasing through digital biochemical screening systems, while the retention of leading pharmacologists is secured by academic freedom and equity options, strengthening the company's potential for developing liver disease medications.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_ETNB_-_89bio-Inc._-_Earnings-per-share-for-the-last-four-quarters "89bio Corp - רווח נקי למניה (EPS TTM) ETNB (תקופה 04.07.2022 - 15.11.2025) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת 89bio Inc (ETNB)
This indicator measures the actual efficiency of profit generation per share annually, excluding distortions from share issuances or buybacks. By analyzing the annual net income per share trend, an investor identifies the reversal point of fundamental momentum, which is critical for 89bio, Inc. (ETNB), as its future pricing power and high margins depend on the successful market launch of its therapy.
